Correction: The effect of dapagliflozin on cardiorespiratory fitness in patients with coronary heart disease and type 2 diabetes mellitus following PCI: a single-center prospective randomized controlled study - Report - MDSpire
Advertisement
Correction: The effect of dapagliflozin on cardiorespiratory fitness in patients with coronary heart disease and type 2 diabetes mellitus following PCI: a single-center prospective randomized controlled study
Correction: Impact of Dapagliflozin on Cardiorespiratory Fitness Post-PCI
Overview
This report corrects data inaccuracies in a study assessing dapagliflozin's impact on cardiorespiratory fitness in individuals with coronary heart disease and type 2 diabetes mellitus post-percutaneous coronary intervention. Key corrections include adjustments to medication proportions and P-values in the study's tables.
Background
Dapagliflozin, an SGLT2 inhibitor, is used in managing type 2 diabetes mellitus (T2DM) and has implications for cardiovascular health, especially in patients with coronary heart disease (CHD). Accurate data reporting is crucial for understanding the drug's efficacy and safety in this population. This correction highlights the importance of data integrity in clinical research.
Data Highlights
Corrections made to Table 1 and Table 6 include:
ACEI medication proportion (Dapagliflozin group): changed from 8(10.03) to 8(14.03).
Nitrates proportion (Non-dapagliflozin group): changed from 38(67.86) to 27(48.21).
BMI (kg/m2) P-value: changed from 0.720 to 0.072.
Key Findings
Corrections to medication proportions and P-values were necessary for accurate data representation.
Dapagliflozin is associated with improved cardiovascular outcomes in patients with T2DM and CHD.
Accurate reporting of clinical trial data is essential for guiding treatment decisions.
Related studies indicate the potential benefits of SGLT2 inhibitors in heart failure management.
Guidelines recommend SGLT2 inhibitors for patients with T2DM at high cardiovascular risk.
Clinical Implications
Clinicians should be aware of the corrected data when interpreting the study's findings. Accurate data is essential for making informed treatment decisions regarding dapagliflozin in patients with T2DM and CHD.
Conclusion
The corrections made to the study data are critical for ensuring the reliability of findings related to dapagliflozin's impact on cardiorespiratory fitness. Ongoing vigilance in data accuracy is necessary in clinical research.
